Central Bank & Trust Co. Acquires 650 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Central Bank & Trust Co. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 50.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,948 shares of the biopharmaceutical company’s stock after purchasing an additional 650 shares during the quarter. Central Bank & Trust Co.’s holdings in Regeneron Pharmaceuticals were worth $2,048,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the business. International Assets Investment Management LLC increased its holdings in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares during the last quarter. Capital International Investors lifted its stake in Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after purchasing an additional 213,038 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after purchasing an additional 184,561 shares during the period. TD Asset Management Inc lifted its holdings in Regeneron Pharmaceuticals by 162.9% during the first quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock valued at $259,402,000 after purchasing an additional 166,998 shares during the last quarter. Finally, Swedbank AB bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $129,257,000. 83.31% of the stock is currently owned by institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 487 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

REGN has been the topic of a number of recent analyst reports. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday. Leerink Partners reiterated a “market perform” rating and issued a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, JPMorgan Chase & Co. reduced their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $1,097.25.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $828.84 on Tuesday. The company has a 50-day simple moving average of $1,051.02 and a two-hundred day simple moving average of $1,040.40. Regeneron Pharmaceuticals, Inc. has a 12-month low of $783.57 and a 12-month high of $1,211.20. The firm has a market cap of $91.37 billion, a price-to-earnings ratio of 20.51, a PEG ratio of 2.90 and a beta of 0.15. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.